uracil has been researched along with DDPAC in 10 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial." | 8.31 | Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. ( Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023) |
| "Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC)." | 8.31 | Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ( Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T, 2023) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 8.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations." | 7.01 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. ( Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS, 2023) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial." | 4.31 | Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. ( Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023) |
| "Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC)." | 4.31 | Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ( Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T, 2023) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 4.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations." | 3.01 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. ( Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coutzac, C | 1 |
| Trouilloud, I | 1 |
| Artru, P | 1 |
| Henriques, J | 1 |
| Masson, T | 1 |
| Doat, S | 1 |
| Bouché, O | 1 |
| Coriat, R | 1 |
| Saint, A | 1 |
| Moulin, V | 1 |
| Vernerey, D | 1 |
| Gallois, C | 1 |
| De La Fouchardière, C | 1 |
| Tougeron, D | 1 |
| Taieb, J | 1 |
| Yoshino, T | 4 |
| Van Cutsem, E | 4 |
| Li, J | 1 |
| Shen, L | 1 |
| Kim, TW | 1 |
| Sriuranpong, V | 1 |
| Xuereb, L | 1 |
| Aubel, P | 1 |
| Fougeray, R | 1 |
| Cattan, V | 1 |
| Amellal, N | 1 |
| Ohtsu, A | 4 |
| Mayer, RJ | 1 |
| Hochster, H | 3 |
| Shitara, K | 3 |
| Mayer, R | 3 |
| Falcone, A | 3 |
| Doi, T | 3 |
| Ilson, DH | 3 |
| Arkenau, HT | 3 |
| George, B | 3 |
| Benhadji, KA | 3 |
| Makris, L | 3 |
| Tabernero, J | 3 |
| Ding, PQ | 1 |
| Dolley, A | 1 |
| Cheung, WY | 1 |
| Victorino, APOS | 1 |
| Meton, F | 1 |
| Mardegan, L | 1 |
| Festa, J | 1 |
| Piranda, DN | 1 |
| Araujo, KB | 1 |
| Hayashi, K | 1 |
| Furuta, M | 1 |
| Furusawa, K | 1 |
| Hamaguchi, T | 1 |
| Watanabe, M | 1 |
| Inokuchi, Y | 1 |
| Onuma, S | 1 |
| Hashimoto, I | 1 |
| Suematsu, H | 1 |
| Nagasawa, S | 1 |
| Kanematsu, K | 1 |
| Yamada, T | 1 |
| Notsu, A | 1 |
| Ogata, T | 1 |
| Oshima, T | 1 |
| Machida, N | 1 |
| Furuse, J | 1 |
| Maeda, S | 1 |
| Kröning, H | 1 |
| Göhler, T | 1 |
| Decker, T | 1 |
| Grundeis, M | 1 |
| Kojouharoff, G | 1 |
| Lipke, J | 1 |
| Semsek, D | 1 |
| Moorahrend, E | 1 |
| Sauer, A | 1 |
| Bruch, HR | 1 |
| Liersch, R | 1 |
| Nusch, A | 1 |
| Vehling-Kaiser, U | 1 |
| Welslau, M | 1 |
| Grunewald, R | 1 |
| Harich, HD | 1 |
| Stephany, M | 1 |
| Uhlig, J | 1 |
| de Buhr, R | 1 |
| Frank, M | 1 |
| Hogrefe, C | 1 |
| Marschner, N | 1 |
| Potthoff, K | 1 |
| Hartmann, F | 1 |
| Reisländer, T | 1 |
| Schwaner, I | 1 |
| Kagawa, Y | 1 |
| Shinozaki, E | 1 |
| Okude, R | 1 |
| Tone, T | 1 |
| Kunitomi, Y | 1 |
| Nakashima, M | 1 |
| Shiroyama, M | 1 |
| Fukuoka, S | 1 |
| Masuishi, T | 1 |
| Takashima, A | 1 |
| Kumekawa, Y | 1 |
| Kajiwara, T | 1 |
| Yamazaki, K | 1 |
| Shimada, Y | 1 |
| Esaki, T | 1 |
| Makiyama, A | 1 |
| Moriwaki, T | 1 |
3 reviews available for uracil and DDPAC
| Article | Year |
|---|---|
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Onc | 2022 |
Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Front | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
2 trials available for uracil and DDPAC
6 other studies available for uracil and DDPAC
| Article | Year |
|---|---|
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Topics: Adult; Aged; Canada; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Frontotem | 2022 |
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotempo | 2023 |
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Topics: Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Japan; Retros | 2023 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |